Abstract
Doublet fluoropyrimidine-based chemotherapy is the standard of care for the first-line treatment of metastatic colorectal cancer (mCRC). However, single fluoropyrimidine-based therapy remains an important alternative. In this article, we highlight the potential impact of a recent trial assessing the addition of bevacizumab to capecitabine in the first-line treatment of mCRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
